Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis

Simple Summary Myelofibrosis (MF) displays the worst prognosis among Philadelphia-negative chronic myeloproliferative neoplasms. There is no curative therapy for MF, except for bone marrow transplantation, which however has a consistent percentage of failure. There is thus an urgent need of novel biomarkers to complement current stratification models and to enable better management of patients. To address this issue, we herein measured the plasma levels of several long noncoding RNAs (lncRNAs). Circulating lncRNAs has been already largely described as potential non-invasive biomarkers in cancers. In our study we unveiled that LINC01268, MALAT1 (both p < 0.0001) and GAS5 (p = 0.0003) plasma levels are significantly higher in MF patients if compared with healthy donors, and their increased plasma levels correlate with several detrimental features in MF. Among them, LINC01268 is an independent variable for both OS (p = 0.0297) and LFS (p = 0.0479), thus representing a putative new biomarker suitable for integrate contemporary prognostic models. Abstract Long non-coding RNAs (lncRNAs) have been recently described as key mediators in the development of hematological malignancies. In the last years, circulating lncRNAs have been proposed as a new class of non-invasive biomarkers for cancer diagnosis and prognosis and to predict treatment response. The present study is aimed to investigate the potential of circulating lncRNAs as non-invasive prognostic biomarkers in myelofibrosis (MF), the most severe among Philadelphia-negative myeloproliferative neoplasms. We detected increased levels of seven circulating lncRNAs in plasma samples of MF patients (n = 143), compared to healthy controls (n = 65). Among these, high levels of LINC01268, MALAT1 or GAS5 correlate with detrimental clinical variables, such as high count of leukocytes and CD34+ cells, severe grade of bone marrow fibrosis and presence of splenomegaly. Strikingly, high plasma levels of LINC01268 (p = 0.0018), GAS5 (p = 0.0008) or MALAT1 (p = 0.0348) are also associated with a poor overall-survival while high levels of LINC01268 correlate with a shorter leukemia-free-survival. Finally, multivariate analysis demonstrated that the plasma level of LINC01268 is an independent prognostic variable, suggesting that, if confirmed in future in an independent patients’ cohort, it could be used for further studies to design an updated classification model for MF patients.

[1]  Michael T. McManus,et al.  Examining the evidence for extracellular RNA function in mammals , 2021, Nature Reviews Genetics.

[2]  M. Cazzola,et al.  Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. , 2021, Blood advances.

[3]  I. Christensen,et al.  Gene expression profile association with poor prognosis in epithelial ovarian cancer patients , 2021, Scientific Reports.

[4]  C. Peano,et al.  Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis , 2021, npj Precision Oncology.

[5]  Maite Huarte,et al.  Gene regulation by long non-coding RNAs and its biological functions , 2020, Nature reviews. Molecular cell biology.

[6]  C. Peano,et al.  Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis , 2020, bioRxiv.

[7]  C. Marcocci,et al.  Circulating Long Non-Coding RNA GAS5 Is Overexpressed in Serum from Osteoporotic Patients and Is Associated with Increased Risk of Bone Fragility , 2020, International journal of molecular sciences.

[8]  M. Tsao,et al.  Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways , 2020, Cancers.

[9]  Qin Zhou,et al.  Long non-coding RNA LINC01268 promotes cell growth and inhibits cell apoptosis by modulating miR-217/SOS1 axis in acute myeloid leukemia , 2020, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[10]  T. Brüning,et al.  Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies , 2020, Biomarker Research.

[11]  Fangfang Xue,et al.  The long non‐coding RNA LOC285758 promotes invasion of acute myeloid leukemia cells by down‐regulating miR‐204‐5p , 2020, FEBS open bio.

[12]  S. Swetter,et al.  Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice , 2019, Melanoma management.

[13]  M. Cuadros,et al.  Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia , 2019, Blood Cancer Journal.

[14]  S. Yeung,et al.  The role of long non-coding RNA GAS5 in cancers , 2019, Cancer management and research.

[15]  Kyle J. Gaulton,et al.  The long noncoding RNA ROCKI regulates inflammatory gene expression , 2019, The EMBO journal.

[16]  A. Tefferi,et al.  20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients , 2018, American journal of hematology.

[17]  A. Tefferi,et al.  20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients , 2018, Blood.

[18]  Y. Li,et al.  Long non-coding RNA LINC00899 as a novel serum biomarker for diagnosis and prognosis prediction of acute myeloid leukemia. , 2018, European review for medical and pharmacological sciences.

[19]  F. Wang,et al.  Long non-coding RNAs in hematopoietic regulation , 2018, Cell regeneration.

[20]  M. Ellis,et al.  Long non-coding RNA MALAT1 suppresses breast cancer metastasis , 2018, Nature Genetics.

[21]  Zhiguo Wang,et al.  MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis , 2018, BMB reports.

[22]  George A. Calin,et al.  Clinical utility of circulating non-coding RNAs — an update , 2018, Nature Reviews Clinical Oncology.

[23]  P. Guglielmelli,et al.  MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  O. Pös,et al.  Circulating cell-free nucleic acids: characteristics and applications , 2018, European Journal of Human Genetics.

[25]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[26]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Gazit,et al.  Neat1 in hematopoietic stem cells , 2017, Oncotarget.

[28]  H. Lodish,et al.  Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. , 2017, Blood.

[29]  A. Vannucchi,et al.  Genetic Risk Assessment in Myeloproliferative Neoplasms , 2017, Mayo Clinic proceedings.

[30]  T. Deng,et al.  MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. , 2017, Oncology letters.

[31]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[32]  A. Tefferi,et al.  Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management , 2016 .

[33]  V. Ugo,et al.  Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study , 2016, Annals of Hematology.

[34]  J. Rinn,et al.  The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan , 2016, Nature.

[35]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[36]  Marta Lionetti,et al.  Long non-coding RNAs in normal and malignant hematopoiesis , 2016, Oncotarget.

[37]  D. Marsh,et al.  Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs , 2016, PloS one.

[38]  A. Tukiendorf,et al.  Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients , 2015, Journal of experimental & clinical cancer research : CR.

[39]  Ayalew Tefferi,et al.  Myeloproliferative Neoplasms A Contemporary Review , 2015 .

[40]  R. Zini,et al.  Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations , 2015, Leukemia & lymphoma.

[41]  Jan-Gowth Chang,et al.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression , 2014, BMC Cancer.

[42]  F. Hou,et al.  Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex , 2014, British Journal of Cancer.

[43]  S. Weissman,et al.  Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells , 2014, RNA biology.

[44]  H. Lodish,et al.  Long noncoding RNAs during normal and malignant hematopoiesis , 2014, International Journal of Hematology.

[45]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[46]  M. L. Bousse-Kerdilès Primary myelofibrosis and the "bad seeds in bad soil" concept , 2012 .

[47]  Cole Trapnell,et al.  Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. , 2011, Genes & development.

[48]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[49]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[50]  N. Davidson,et al.  Gene expression profiling of breast cancer. , 2008, Advances in surgery.

[51]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[52]  R. Weiss,et al.  EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. , 2007, Blood.

[53]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[54]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[55]  L. Kwak,et al.  Detection of tumor messenger RNA in the serum of patients with malignant melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  S. Leung,et al.  Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. , 1999, Clinical chemistry.

[57]  S. Lewis,et al.  Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders , 1984, British journal of haematology.

[58]  T Giorgino,et al.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.

[59]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .